Androgen Restored Contraception
ARC, Triple Hormone Contraceptive, Triple OC, Female-Balance Pill, Pill Plus, EE/DRSP/DHEA Pill
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Short-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): ANI Pharmaceuticals, Pantarhei Bioscience
Details
- API: Ethinylestradiol, Drospirenone, Prasterone
- Target: Estrogen Receptor, Progesterone Receptor, Androgen Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Undetermined
- Regimen: 1 Pill/Day
- MPT: Not Potential MPT
Product Status
No additional publications indicating development since 2018
History
Extensively evaluated from 2013 - 2016, culminating in a Ph II trial that found some positive impact on preservation/restoration of sexual function